VRBCF
Virbac S.A. · Healthcare
Virbac S.A. · Healthcare
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Healthcare
Drug Manufacturers - General
6,365
2013-04-17
0.81

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights March, 31 2026 8 390 660 Gross total of voting rights : 12 707 254 Net total* of voting rights : 12 694 418 Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal health NYSE Euronext - Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel.

Virbac SA (VRBCF) Q4 2025 Earnings Call Transcript

Public release of Virbac Consolidated Accounts at 31 December 2025. The Group released its 2025 Consolidated Accounts.

A robust adjusted EBIT margin² of 16.3% at CERS, driven by solid organic revenue growth of 7.9% Solid 2025 dynamic with annual revenue up +7.9% at CERS; with strong momentum in key categories and countries. Volume/mix effect of ~+5%, completed by price increase of ~+3% Adjusted EBIT (before amortization of assets arising from acquisitions) margin of 16.3% at CERS despite: temporary shutdown of an antigen's production site and higher inventory write-offs in FY25 partially offset by a solid underlying performance on sales prices and product mix and; improving operating expense to revenue ratio.

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights February, 28 2026 8 390 660 Gross total of voting rights : 12 703 749 Net total* of voting rights : 12 690 913 Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal health NYSE Euronext - Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel.

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 Date Total number of shares representing the share capital Total number of voting rights January, 31 2026 8 390 660 Gross total of voting rights : 12 704 131 Net total* of voting rights : 12 691 295 Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal health NYSE Euronext - Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel.
No recent filings